SCHEMBL1048259

SCHEMBL1048259

O=Cc1ccc(-c2cnc(Nc3ccccc3)c3c(=O)[nH]ccc23)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 3/20 0.43
TTBK1 Q5TCY1 2/20 0.38
TTBK2 Q6IQ55 2/20 0.38
KDM4E B2RXH2 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
ELANE P08246 1/20 0.35
BRD4 O60885 3/20 0.35
ALDH1A1 P00352 1/20 0.34
JAK2 O60674 4/20 0.33
JAK1 P23458 3/20 0.33
EGFR P00533 2/20 0.33
AURKB Q96GD4 2/20 0.33
INCENP Q9NQS7 1/20 0.33
AURKA O14965 1/20 0.33
CYP2E1 P05181 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2B6 P20813 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1047814 0.91 CYP3A4 (0.45) ZAP70KDM4ELMNAPOLBBRD4
SCHEMBL1049635 0.80 ZAP70 (0.53) ZAP70TTBK1TTBK2BRD4JAK2
SCHEMBL1048572 0.76 ZAP70 (0.45) ZAP70TTBK1TTBK2BRD4JAK2
SCHEMBL1048999 0.76 ZAP70 (0.49) ZAP70TTBK1TTBK2BRD4JAK2
SCHEMBL1046300 0.75 ALDH1A1 (0.51) ZAP70TTBK1TTBK2LMNABRD4
SCHEMBL1048942 0.75 ZAP70 (0.48) ZAP70TTBK1TTBK2KDM4ELMNA
SCHEMBL1043299 0.75 JAK2 (0.49) ZAP70TTBK1TTBK2POLBBRD4
SCHEMBL1049397 0.74 NUDT1 (0.48) ZAP70TTBK1TTBK2KDM4ELMNA
SCHEMBL1044222 0.73 LMNA (0.51) ZAP70TTBK1TTBK2LMNAPOLB
SCHEMBL1048512 0.73 ZAP70 (0.47) ZAP70TTBK1TTBK2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546370-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-10-01 US claimed
CN-101990539-A Compounds and compositions as kinase inhibitors IRM LLC 2011-03-23 CN claimed
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
EP-2238137-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2010-10-13 EP claimed
WO-2009097287-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2009-08-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003798-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FYN, SYK, RET ZAP70 4/4885TTBK1 488/4885TTBK2 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.